C
Cristina Cruz
Researcher at Hebron University
Publications - 44
Citations - 4603
Cristina Cruz is an academic researcher from Hebron University. The author has contributed to research in topics: Breast cancer & PARP inhibitor. The author has an hindex of 18, co-authored 43 publications receiving 3607 citations. Previous affiliations of Cristina Cruz include University of Barcelona & Stony Brook University.
Papers
More filters
Journal ArticleDOI
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles,Joseph Paul Eder,Gregg Fine,Fadi Braiteh,Yohann Loriot,Cristina Cruz,Joaquim Bellmunt,Howard A. Burris,Daniel P. Petrylak,Siew-leng Melinda Teng,Xiaodong Shen,Zachary Boyd,Priti S. Hegde,Daniel S. Chen,Nicholas J. Vogelzang +14 more
TL;DR: It is demonstrated that tumours expressing PD-L1-positive tumour-infiltrating immune cells had particularly high response rates, and patients with UBC, who are often older and have a higher incidence of renal impairment, may be better able to tolerate MPDL3280A versus chemotherapy.
Journal ArticleDOI
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.
Leisha A. Emens,Leisha A. Emens,Cristina Cruz,Joseph Paul Eder,Fadi Braiteh,Cathie Chung,Sara M. Tolaney,Irene Kuter,Rita Nanda,Philippe A. Cassier,Jean Pierre Delord,Michael S. Gordon,Ehab Elgabry,Ching-Wei Chang,Indrani Sarkar,William Grossman,Carol O'Hear,Marcella Fassò,Luciana Molinero,Peter Schmid +19 more
TL;DR: Single-agent atezolizumab was well tolerated and provided durable clinical benefit in patients with mTNBC with stable or responding disease and in earlier lines of treatment.
Journal ArticleDOI
A decade of clinical development of PARP inhibitors in perspective.
Joaquin Mateo,Christopher J. Lord,Violeta Serra,Andrew Tutt,Andrew Tutt,Judith Balmaña,Marta Castroviejo-Bermejo,Cristina Cruz,Ana Oaknin,Stan B. Kaye,Stan B. Kaye,J.S. de Bono,J.S. de Bono +12 more
TL;DR: Over the past 10 years, knowledge on the mechanism of action of PARP inhibitor as well as how tumours become resistant has been extended, and the opportunities for expanding the precision medicine approach with PARP inhibitors are discussed.
Journal ArticleDOI
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
Cristina Cruz,Marta Castroviejo-Bermejo,Sara Gutiérrez-Enríquez,Alba Llop-Guevara,Yasir H. Ibrahim,Albert Gris-Oliver,Sandra Bonache,Beatriz Morancho,Alejandra Bruna,Oscar M. Rueda,Zhongwu Lai,Urszula M. Polanska,Gemma N Jones,Petra Kristel,L. de Bustos,Mario Guzmán,Olga Rodriguez,Judit Grueso,Gemma Montalban,Ginevra Caratu,Francesco M. Mancuso,Roberta Fasani,J. Jimenez,William J. Howat,Brian Dougherty,Ana Vivancos,Paolo Nuciforo,Xavier Serres-Créixams,Isabel T. Rubio,Ana Oaknin,Elaine Cadogan,J.C. Barrett,Carlos Caldas,Carlos Caldas,J. Baselga,Cristina Saura,J. Cortés,Joaquín Arribas,Jos Jonkers,Orland Diez,Mark J. O'Connor,Judith Balmaña,Violeta Serra +42 more
TL;DR: In this paper, the in vivo mechanisms of PARPi resistance in gBRCA1 patient-derived tumor xenografts (PDXs) exhibiting differential response to PARPi were investigated.
Journal ArticleDOI
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
Shawn F. Johnson,Cristina Cruz,Ann Katrin Greifenberg,Ann Katrin Greifenberg,Sofia Dust,Sofia Dust,Daniel G. Stover,Daniel G. Stover,David Chi,Benjamin Primack,Shiliang Cao,Andrea J. Bernhardy,Rhiannon Coulson,Jean Bernard Lazaro,Bose Kochupurakkal,Heather Sun,Christine Unitt,Lisa A. Moreau,Kristopher A. Sarosiek,Maurizio Scaltriti,Dejan Juric,José Baselga,Andrea L. Richardson,Scott J. Rodig,Alan D. D'Andrea,Judith Balmaña,Neil Johnson,Matthias Geyer,Matthias Geyer,Violeta Serra,Elgene Lim,Elgene Lim,Geoffrey I. Shapiro,Geoffrey I. Shapiro +33 more
TL;DR: Dinaciclib augments the degree of response in a PARP-inhibitor-sensitive model, converting tumor growth inhibition to durable regression and support the broad use of combined CDK12 and PARP inhibition in TNBC.